From listening to the FDA adcomm on Paxlovid today it’s evident that clinicians desperately want an oral COVID antiviral that’s better and safer (fewer DDIs) than Paxlovid.
Oh how happy we would both be if EDP-235 is that anti-viral! :)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.